苑东生物：向参股公司增资暨关联交易完成

Core Viewpoint - The company has increased its investment in Shanghai Chaoyang Pharmaceutical Co., Ltd., resulting in a controlling stake and consolidation into its financial statements [1] Group 1: Investment Details - The company’s wholly-owned subsidiary, Yuandong Bio Investment Management (Shanghai) Co., Ltd., has invested 85.71 million yuan in Shanghai Chaoyang Pharmaceutical [1] - The investment price is set at 2.27 yuan per registered capital, corresponding to a registered capital of 37.71 million yuan for Shanghai Chaoyang [1] - Following this investment, the registered capital of Shanghai Chaoyang will increase from 88 million yuan to 126 million yuan [1] Group 2: Ownership Changes - The company's indirect ownership stake in Shanghai Chaoyang will rise from 30.68% to 51.48% [1] - As a result of this increase, Shanghai Chaoyang will become a controlled subsidiary of the company [1] - The financial results of Shanghai Chaoyang will now be included in the company’s consolidated financial statements [1]